Skip to main content

7-Hydroxymitragynine Facts

Opioid; Indole alkaloid; Mu-opioid receptor agonist

Description

7-Hydroxymitragynine (7-HMG) — 7-OH — is a semi-synthetic opioid of the monoterpenoid indole alkaloid class. It activates opioid receptors in the brain, producing pain suppression, sedation, and euphoria.

Subjective effects include pain relief, sedation, euphoria, and anxiolysis. The experience is defined by what it removes: discomfort recedes, and body and mind settle into heavy calm.

7-HMG produces physical dependence and opioid withdrawal; respiratory depression 4.5 times more potent than morphine[1] makes breathing failure the primary lethal risk. Tolerance is shared bidirectionally with morphine,[2] and combining with any other depressant sharply amplifies the risk of fatal breathing failure.

Dose and durationby route · individual sensitivity varies

Oral

No dose recorded for this route. The timings are not a dose guide.

Starts in 20 – 45 minLasts 4 – 8 hoursAfter-effects 6 – 24 hours

Body and dependence

Acute toxicity
High
Chronic toxicity
Moderate
Physical dependence
High
Psychological dependence
High
Withdrawal
Severe · medical supervision
Compulsive redosing
High

Tolerance

Builds
Moderate
Fully resets after
Not recorded
Carries over to
morphine; mu-opioid agonists (class)

Effectslikely at a common dose

Perception
none likely · 4 possible, including Spatial disorientation, Visual acuity suppression, Visual haze / noise
Body
Body high; Muscle relaxation; Pain suppression; Pupil constriction; Sedation; +17 possible, including Nausea, Dizziness, Motor control impairment
Thinking
none likely · 12 possible, including Analysis suppression, Cognitive impairment, Compulsive redosing urge
Feeling
Euphoria; +2 possible
Self
none likely · 3 possible, including Craving, Social disconnection
Time
none likely · 2 possible, including Temporal disorientation

Who shouldn't take it

Absolute
Concurrent CNS depressant use; Severe respiratory disease; Head injury with raised intracranial pressure; Severe hepatic impairment; Paralytic ileus
Relative
Active substance use disorder; Moderate hepatic impairment; Pregnancy; CYP3A4 inhibitor co-administration

Combinations60 recorded

Lethal (4)
Benzodiazepines, Barbiturates; GHB, Baclofen; GHB, GBL; Local anesthetics
Dangerous (28)
Alpha-2 adrenergic receptor antagonist; Amphetamines; Anticholinergics; Antihistamines; Antipsychotics; Benzodiazepines; Buprenorphine, Kratom; Cannabis, THC; Clonidine, Guanfacine; Gabapentin, Pregabalin; MAOIs; MDMA, Amphetamines; MDMA, MDA; Naltrexone; NRIs; SNRIs; SSRIs; Stimulants; Synthetic cannabinoids; THC; Caffeine; CBD; Glutamate modulator; Huperzine A; and 4 more, see full page
Caution (19)
See full page: psychedex.org/substances/7-hydroxymitragynine
Not graded (9)
Not listed never means safe.

Seek help immediately if

  • Unresponsive / can't be woken, even to a firm sternal rub
  • Slow, shallow, or stopped breathing
  • Pinpoint pupils
  • Blue/grey lips, fingertips, or skin (cyanosis)
  • Limp body; pale, clammy skin
  • Choking or gurgling sounds ("death rattle")
  • Slow, erratic, or absent pulse

What to do

  1. Try to wake them — shout their name, firm sternal rub
  2. Call emergency services immediately
  3. Administer naloxone if available
  4. Give rescue breaths (or CPR if there is no pulse)
  5. Place them in the recovery position
  6. Stay with them; re-dose naloxone every 2–3 minutes if there is no response
Reversal agent
Naloxone (Narcan) — opioid antagonist. May require repeated doses; its effect can wear off before the opioid does.

With prompt naloxone and rescue breathing, reversal is usually rapid. Because naloxone can wear off before the opioid — especially with long-acting opioids (methadone) or high-potency ones (fentanyl) — a period of monitoring is needed even after the person revives.

988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE

Version r1.a2 · Not medical advice

References

  1. [1]
    ^Zuarth Gonzalez JD, Ragsdale AK, Mukhopadhyay S, McCurdy CR, McMahon LR, Obeng S, Wilkerson JL (2025) Mitragynine and 7-hydroxymitragynine: Bidirectional effects on breathing in rats. — Journal of Pharmacology and Experimental Therapeutics doi:10.1016/j.jpet.2025.103720
  2. [2]
    ^Matsumoto K, Horie S, Takayama H, Ishikawa H, Aimi N, Ponglux D, Murayama T, Watanabe K (2005) Antinociception, tolerance and withdrawal symptoms induced by 7-hydroxymitragynine, an alkaloid from the Thai medicinal herb Mitragyna speciosa. — Life Sciences PMID:16169018
Print version
Report an issue